Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Pfizer"


25 mentions found


Cramer: Pfizer's Covid sales tapered off much quicker than anyone expectedCNBC's Jim Cramer breaks down his take on Pfizer shares.
Persons: Cramer, Pfizer's, Jim Cramer Organizations: Pfizer
CNBC Daily Open: Apple upgrades Siri with AI
  + stars: | 2024-06-11 | by ( Abid Ali | ) www.cnbc.com   time to read: +3 min
This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. Apple IntelligenceShares of Apple fell 1.9% after the iPhone maker delivered its long-awaited AI strategy. Siri will get an upgrade with Apple Intelligence and access to OpenAI's ChatGPT. Investors are concerned Apple had fallen behind its rivals, Microsoft and Google, in the race to deliver AI services and tools.
Persons: Goldman Sachs, Siri, Apple, Elon Musk's, Chris Ailman, CNBC's, Ailman, CalSTRS, Elliott, Moderna, Tesla, Elon, Bernstein Organizations: CNBC, Nasdaq, Technology, Nvidia, Meta, Microsoft, Dow Jones, Apple Intelligence, Apple, Investors, Google, California State Teachers, Elliott, Southwest, Elliott Management, Southwest Airlines, Boeing, Pfizer, Novavax Locations: U.S
Moderna on Monday said its combination vaccine that targets both Covid-19 and the flu was more effective than existing standalone shots for those viruses in a late-stage trial. Moderna's messenger RNA combination shot, called mRNA-1083, is made up of both the company's vaccine candidate for seasonal influenza and a newer, "next-generation" version of its Covid shot. The study compared the combination shot with an enhanced flu vaccine called Fluzone HD and Moderna's currently licensed Covid shot, Spikevax, in one group of patients ages 65 and above. Moderna is also developing a combination shot targeting the flu and RSV, and another vaccine targeting all three respiratory viruses: Covid, flu and RSV. Meanwhile, Pfizer and BioNTech also are studying a vaccine that targets both Covid and the flu in a late-stage trial.
Persons: Stephane Bancel, Novavax, Bancel, Moderna, BioNTech Organizations: Pfizer, Novavax, Moderna, Covid Locations: U.S
But the virus can also cause severe illness in adults 50 and up — or even younger — with underlying chronic conditions such as asthma, diabetes and congestive heart failure. GSK's shot won't reach that new patient population just yet. Safety data in adults ages 50 to 59 was also consistent with data in adults 60 and above, according to GSK. Regulatory agencies in Europe, Japan and other areas are currently reviewing GSK's application to expand Arexvy's approval to high-risk adults ages 50 to 59. GSK's shot is approved in nearly 50 countries, a spokesperson for the company told CNBC.
Persons: Phil Dormitzer, Dormitzer, Luke Miels, Arexvy, GSK's Organizations: Drug Administration, GSK, FDA, Centers for Disease Control, CNBC, CDC, Pfizer, Moderna, U.S Locations: British, Europe, Japan
“We saw that with the mRNA (messenger RNA) vaccines that it can be a good messenger,” says Cech. The Catalyst by Thomas R. Cech W W NortonYou mentioned in “The Catalyst” that research on RNA has been around since the ‘50s. What is something that most people get wrong about mRNA vaccines, such as the Covid-19 ones? Thomas R. Cech in a lab in 1984, five years before he won the Nobel Prize in Chemistry. How does this apply to DNA, RNA, mRNA and CRISPR?
Persons: you’re, , Thomas R, Cech, ” Cech, Sidney Altman, he’s, Norton, It’s, Thomas R . Cech, Organizations: CNN, Pfizer, DNA, University of Colorado, Denver Post, Rotary Clubs, Lions Locations: Moderna, University of Colorado , Boulder, Boulder , Colorado, China, Cambridge , Massachusetts, United States, Germany
Final Trades: Pfizer, Alphabet, Ventas and ASML Holding
  + stars: | 2024-06-04 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Pfizer, Alphabet, Ventas and ASML HoldingThe Investment Committee share their top stocks to watch for the second half.
Organizations: Pfizer, ASML, Investment
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO: Cancer drugs will be our next big contribution to the worldPfizer CEO Albert Bourla joins 'Squawk on the Street' to discuss the company's recent lung cancer drug data, how the drug could change the company's revenues, and more.
Persons: Albert Bourla Organizations: Pfizer, Cancer
CNBC Daily Open: Opec extends cuts, Nvidia showcases new chip
  + stars: | 2024-06-03 | by ( Abid Ali | ) www.cnbc.com   time to read: +3 min
This report is from today's CNBC Daily Open, our international markets newsletter. CNBC Daily Open brings investors up to speed on everything they need to know, no matter where they are. OPEC+ extends cutsOPEC and it allies agreed to extend official crude production cuts into 2025 amid lackluster demand. Saudi Arabia's energy minister Prince Abdulaziz bin Salman said OPEC+ wants concrete rate cuts before factoring in the potential impact on energy demand. New AI chip RubinNvidia unveiled its next generation artificial intelligence chip, Rubin, a mere three months after launching its Blackwell model.
Persons: Prince Abdulaziz bin Salman, Rubin, Blackwell, Dow, UnitedHealth, Bill Ackman, It's, Michael Khouw Organizations: CNBC, Saudi Aramco, Rubin Nvidia, AMD, Intel, Microsoft, Google, Dow Jones, Federal, Dow, Nasdaq, Nvidia, Tesla, Pershing, Moderna, Drug Administration, GSK, Pfizer Locations: OPEC, Saudi Arabia, Russia, Saudi, U.S, Moderna
Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. LONDON — Shares of British pharmaceuticals giant GSK plunged 9% Monday, after a U.S. court ruled that scientific evidence could be presented in a stack of lawsuits relating to the discontinued heartburn drug Zantac. The Delaware State Court late on Friday ruled that plaintiffs' expert witnesses could testify in the roughly 75,000 cases alleging the once-popular drug ranitidine — sold under the brand name Zantac in the U.S. — may cause cancer. The companies involved deny there is a scientific consensus that the drug can be linked to any later development of cancers. In a statement Friday, GSK said it disagreed with the latest Delaware ruling and would immediately seek an appeal.
Persons: ranitidine —, Brent Wisner, Wisner Baum, Zantac Organizations: GlaxoSmithKline, Stevenage, GSK, Delaware State Court, France's, Pfizer, Germany's Locations: Britain, Delaware, U.S, France's Sanofi
The Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial virus for adults ages 60 and above, the company's second-ever product to enter the U.S. market. The approval of Moderna's shot is based on a late-stage trial on older adults, who are more vulnerable to severe cases of RSV. The company's shot is also the only RSV vaccine to be available in a pre-filled syringe, which is designed to make it easier to administer to patients. An advisory panel to the CDC will vote in June on recommendations for the use and intended population of Moderna's shot. Moderna's full-year 2024 sales guidance of roughly $4 billion includes revenue from its RSV vaccine.
Persons: Moderna's, Stéphane Bancel Organizations: Drug Administration, Moderna, Centers for Disease Control, CDC, GSK, Pfizer Locations: U.S
CHICAGO — Pfizer on Friday said its drug for an advanced form of lung cancer showed promising long-term results in a late-stage trial, which may help establish it as the new standard treatment for the condition. The drug, called Lorbrena, also cut the risk of the cancer progressing in patients' brains. Only about 5% of all non-small cell lung cancer patients have the mutation, which causes cancer cells to grow and spread abnormally. But Pfizer's drug isn't currently considered the standard – or the most appropriate and widely used – treatment for the condition. Nearly 300 people in the trial either received Lorbrena or Pfizer's older lung cancer drug Xalkori.
Persons: isn't, Chris Boshoff, Lorbrena, David Spigel, Sarah Cannon, Spigel, Andrew Berens, Pfizer's Boshoff Organizations: CHICAGO, Pfizer, CNBC, Lorbrena's, American Society of Clinical Oncology, Clinical Oncology, Sarah, Sarah Cannon Research Institute, Lorbrena, Leerink Locations: U.S, Chicago
Some stocks on Wall Street are absolutely hated by analysts and investors, but their fundamentals are improving, leaving a potential buying opportunity for contrarian investors, according to UBS. Most analysts currently covering the stock have assigned it a hold rating, with predicted upside of about 16% to consensus price targets. "The iconic automaker continues to enjoy strong profits from its core markets and a policy driven investment cycle in the U.S," the analyst wrote. Most analysts have assigned Airbnb stock a hold rating. The analyst consensus has shares at a hold rating, with predictions suggesting the stock could rise an average of 26% from its Thursday close.
Persons: Jonathan Golub, Bernstein, Daniel Roeska's, Wedbush, Scott Devitt, Ben Chaiken, Jan, Chaiken, Clorox, Estee Lauder, — CNBC's Michael Bloom Organizations: UBS, Stocks, Wall, Ford Motor, Ford, Cruise, Mizuho, Pfizer, Gartner, Northern Trust
However, investors can boost their performance when accounting for reinvesting dividends. The stock has a dividend yield of 4.2%, which is just a snapshot of how much it pays currently. The stock has a dividend yield of 3.1%. If you're a long-term investor, you're dollar-cost averaging," she said. Names on her radar these days include Amgen , which is yielding about 3%, and Southern Copper , which has a dividend yield of 3.2%.
Persons: Goldman Sachs, Dow, it's, Kim Abmeyer, Abmeyer, — CNBC's Chris Hayes Organizations: Dow Jones, UnitedHealth, Microsoft, Abmeyer Wealth Management, Dow, CNBC Pro, Chevron, Pfizer Locations: Wednesday's, Dallas, Chevron
Google DeepMind co-founder and Chief Executive Officer Demis Hassabis gives a conference during the Mobile World Congress (MWC), the telecom industry's biggest annual gathering, in Barcelona on February 26, 2024. The CEOs of artificial intelligence heavyweights Google DeepMind, Microsoft AI, Anthropic and Mistral AI are among the elite list of business and political leaders attending a secretive meeting kicking off in Madrid, Spain, on Thursday. AI will once again dominate discussions at the annual Bilderberg Meeting after catapulting onto the agenda last year following the meteoric rise of the burgeoning technology. U.S. Deputy Treasury Secretary Wally Adeyemo, Ukrainian Foreign Minister Dmytro Kuleba and NATO Secretary General Jens Stoltenberg are also among the political figures who will attend for geopolitical discussions including on China and Russia. According to its organizers, the closed nature of the event aims to foster "informal discussions about major issues."
Persons: Demis Hassabis, Jane Fraser, Eric Schmidt, Albert Bourla, Wael Sawan, Peter Thiel, Wally Adeyemo, Dmytro Kuleba, Jens Stoltenberg Organizations: Google, Mobile World Congress, MWC, Microsoft, Mistral, Citigroup, Pfizer, NATO, Chatham House, Economic Locations: Barcelona, Madrid, Spain, Ukrainian, China, Russia, Spanish, Chatham, Davos, Switzerland
Cramer's Lightning Round: Apple is a buy
  + stars: | 2024-05-28 | by ( Julie Coleman | ) www.cnbc.com   time to read: +1 min
Stock Chart Icon Stock chart icon Datadog's year-to-date stock performance. Stock Chart Icon Stock chart icon Axcelis Technologies' year-to-date stock performance. Stock Chart Icon Stock chart icon Tegna's year-to-date stock performance. Stock Chart Icon Stock chart icon Bristol-Myers' year-to-date stock performance. Stock Chart Icon Stock chart icon Palantir's year-to-date stock performance.
Persons: Let's, Myers, Rowe Price's, Rowe Price Organizations: Technologies, Axcelis Technologies, Novo, Novo Nordisk, Bristol, Myers, Pfizer Locations: Bristol
Brandon Bell | Getty ImagesU.S. health officials are monitoring and preparing to combat bird flu in humans, even as they stress that the risk to the general public remains low. An Australian child was also recently infected with bird flu, the country announced on Tuesday. In rare cases, bird flu viruses spread to humans and can cause mild to severe symptoms that can require hospitalization. The Food and Drug Administration would need to approve bird flu vaccines before they roll out. Potential mRNA shotsU.S. health officials are also in talks with messenger RNA vaccine makers about potential bird flu shots for humans.
Persons: Brandon Bell, Andrew Pekosz, Pekosz, Peter Chin, That's, Hong Organizations: Getty, Disease Control, U.S ., Human Services Department, CNBC, Johns Hopkins Bloomberg School of Public Health, CDC, HHS, NBC News, UCSF Health, Drug Administration, FDA, Pfizer, Moderna Locations: Quemado , Texas, Michigan, Australian, U.S
The announcement is in addition to another $4 billion cost-cutting effort, which Pfizer announced last year as demand for its Covid vaccine and oral drug Paxlovid slumped. One-time costs related to the initial stage of cuts are expected to be about $1.7 billion, including severance for an unspecified number of laid-off employees. Pfizer also expects the program to involve "product portfolio enhancements" and changes to the company's manufacturing and supply network, a spokesperson told CNBC. "The program will focus on streamlining our ways of working, reducing complexity and increasing productivity in Pfizer Global Supply," the spokesperson said in a statement. Pfizer is trying to shore up investor sentiment after its shares fell nearly 50% in 2023, making it the worst-performing pharmaceutical stock last year.
Persons: Paxlovid, Wall, Albert Bourla Organizations: Pfizer, CNBC, Pfizer Global Supply Locations: New York City
Structure Therapeutics is an overlooked stock that could surge on the GLP-1 weight loss craze. "Meaningful upside from even a small piece of unprecedentedly large GLP-1 market," JPMorgan said. AdvertisementStructure Therapeutics is developing the drug candidate dubbed "1290," which is a "pure-play option" for the GLP-1 weight loss market, according to JPMorgan. JPMorgan said early results suggest the drug candidate offers "on par" weight loss results for patients with "no major concerns on safety." Advertisement"We think GPCR's market share in the oral market can approach 5% over time in an unprecedentedly large market.
Persons: , Eli Lilly, Eli, orforglipron, Eli Lilly's Organizations: Therapeutics, JPMorgan, Service, Novo Nordisk, GLPP, Nasdaq
CNN —The US Centers for Disease Control and Prevention is urging doctors to be on the lookout for potentially deadly meningococcal disease linked to travel to Saudi Arabia. Meningococcal disease is highly contagious among unvaccinated people. Meningococcal disease, including meningitis, is an uncommon illness caused by the bacteria Neisseria meningitidis. Meningococcal disease can be treated with antibiotics if it’s caught early enough. One such instance is before travel to countries where meningococcal disease is more common.
Persons: Prophet Muhammad, it’s, serogroup C, Dr, Sanjay Gupta Organizations: CNN, Centers for Disease Control, Research, CDC, Pfizer, Hajj, Health Alert Network, CNN Health Locations: Saudi Arabia, Mecca, United States, France, United Kingdom, People
Dan Sundheim's D1 Capital Partners raised its stake by more than 400% in a live entertainment stock during the first quarter, while reallocating funds across major technology winners. Keeping with the entertainment theme, Sundheim also opened a fresh $151 million position in music streamer Spotify Technology . Meta was the firm's fourth-largest position, totaling $382 million at the end of the period, despite a 37% cut. The hedge fund amassed a fresh $218 million stake in Pfizer during the period, making it the firm's 10 largest holding. D1 Capital also opened a position in UnitedHealth , while trimming Elevance Health and diabetes and medical device maker Insulet .
Persons: Dan Sundheim's, Sundheim, Meta, Philip Morris Organizations: Capital Partners, Entertainment, Spotify, Big Tech, Microsoft, Meta, Philip Morris International, Pfizer, D1, GE Vernova, Royal, Mastercard, Visa Locations: UnitedHealth, Royal Caribbean
Stock Chart Icon Stock chart icon The Dow, all-timeThe average was created by Charles Dow in 1896 with just 12 industrial stocks. Paired with the Dow Jones Transportation Average , the two were collectively meant to offer a gauge for the broader economy. The sole caveat: No utility or transportation stocks are included, given the existence of the Dow Jones Utility Average and Transportation Average. 1972: Dow hits 1,000It may be hard to imagine given the recent achievement, but the Dow traded below 1,000 until the early 1970s. The Dow saw its worst year since 2008 in 2022, though 2023's rebound allowed the index to erase those losses.
Persons: Spencer Platt, Dow, Charles Dow, There's, Richard Nixon, Alcoa Esmark, Du Pont, Dow didn't, Walt Disney, Eastman Kodak Merck Alcoa ExxonMobil Phillip Morris, T General Motors Sears, Morgan, Phillip Morris, Walmart Du Pont J.P, Morgan Chase Walt, Donald Trump, General Electric Nike American Express Goldman Sachs, Morgan Chase, Johnson, Joe Biden, Trump, Goldman Sachs, Gamble Amgen, Organizations: New York Stock Exchange, Getty, Dow Jones, Dow Jones Transportation, P Global, Dow, CNBC, General Foods, Harvester, Chevron, Procter, Gamble, Alcoa, Manville, ExxonMobil, Illinois Glass American Tobacco General Electric Procter, General Foods Sears Roebuck AT, T General Motors Texaco Bethlehem Steel, T General Motors Texaco Bethlehem Steel Goodyear Union Carbide Chevron Honeywell United Technologies Chrysler International Harvester US, Nickel Westinghouse Electric Eastman Kodak International, Woolworth, Oasis, Eastman Kodak Merck Alcoa ExxonMobil, Express General Electric Procter, Gamble AT, T General Motors, T General Motors Sears Roebuck Bethlehem Steel Goodyear Texaco Boeing Honeywell Union Carbide Caterpillar IBM United Technologies Chevron International, Walt Disney, Morgan Chase Westinghouse, Apple, Microsoft, Sears and Union Carbide, Eastman Kodak Johnson, Johnson Alcoa ExxonMobil, American Express General Electric Merck AT, T, Goodyear Procter & Gamble Caterpillar Hewlett, Packard Sears, Chevron Honeywell Union Carbide Citigroup IBM United Technologies, Walmart, Morgan Chase Walt Disney, Visa, Travelers, Nike, General Electric Nike American Express, General Electric Nike American Express Goldman Sachs Pfizer Apple Home Depot Procter, Gamble Boeing IBM Travelers Caterpillar Intel United Technologies Chevron, Morgan Chase UnitedHealth, Cisco Systems Johnson, Johnson Verizon, Cola McDonald’s, Du Pont Merck Walmart ExxonMobil Microsoft Corporation Walt Disney, Exxon Mobil, Walgreens Boots Alliance, Goldman Sachs Nike American Express Home Depot Procter, Gamble Amgen Honeywell, Apple Intel Travelers Cos Boeing IBM, Caterpillar Johnson, Johnson Verizon Chevron, Cisco Systems, Walgreens, Alliance Coca Cola Merck Walmart Dow Microsoft Walt Disney Locations: New York City, T General Motors Texaco Bethlehem Steel Goodyear, America
As part of the program, called Break Through Tech A.I., Ms. Prudencio completed an intensive class developed by Cornell Tech faculty with input from a few tech executives. These are the kinds of important learning and career opportunities that can help computing majors land jobs in fast-moving fields like A.I. But students like Ms. Prudencio, who attend public colleges not known for top computing programs, often face challenges gaining access to them. “I was never made aware of health tech before my project with Pfizer,” said Ms. Prudencio, 20, who works part time at a tennis center. Now she hopes to pursue a career in health A.I.
Persons: Chelsea Prudencio, Prudencio, , Organizations: Chelsea, Baruch College, Cornell Tech, Pfizer, Citigroup Locations: Manhattan
Final Trades: Pfizer, Vertex, Freeport-McMoran and Qualcomm
  + stars: | 2024-05-14 | by ( ) www.cnbc.com   time to read: 1 min
In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Pfizer, Vertex, Freeport-McMoran and QualcommThe Investment Committee give you their top stocks to watch for the second half.
Organizations: Pfizer, Vertex, McMoran, Qualcomm, Investment Locations: Freeport
Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit. Pfizer said it would invest 500 million euros ($538.5 million) in France to build up its research and development work in the country, while AstraZeneca announced an investment of $388 million for its site at Dunkirk. France announced earlier on Sunday 100 new jobs in Paris at Wall Street bank Morgan Stanley, and investments from other firms such as German aviation company Lilium . Macron wants to burnish Paris' role as a top European business capital, although it has traditionally lagged New York and London on a global scale. The survey ranked Paris in 14th position.
Persons: Emmanuel Macron, Morgan Stanley, Macron, Paris Organizations: Pfizer, AstraZeneca, Wall, New York, London Locations: France, Dunkirk, Paris, New York, London, New
A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands. Novavax on Friday said it has signed a multibillion-dollar deal with French drugmaker Sanofi to co-commercialize the company's Covid vaccine starting next year and develop combination shots targeting the coronavirus and the flu, among other efforts. Part of the deal allows Sanofi to use Novavax's Covid shot and flagship vaccine technology, Matrix-M adjuvant, to develop new vaccine products. Novavax is also entitled to royalty payments on Sanofi's sales of its Covid vaccine and combination shots targeting coronavirus and the flu. Under the deal, Sanofi will also take a less than 5% stake in Novavax.
Persons: Novavax, Sanofi, John Jacobs, Jacobs Organizations: Dutch Health Service Organization, French, CNBC, Health, Pfizer, Moderna, Sanofi Locations: The Hague, Netherlands, Novavax
Total: 25